Spectronics Corporation v. H.B. Fuller Company, Inc., and H.B. Fuller Automotive Products, Inc.

940 F.2d 631, 19 U.S.P.Q. 2d (BNA) 1545, 1991 U.S. App. LEXIS 16676, 1991 WL 138501
CourtCourt of Appeals for the Federal Circuit
DecidedJuly 29, 1991
Docket91-1041
StatusPublished
Cited by108 cases

This text of 940 F.2d 631 (Spectronics Corporation v. H.B. Fuller Company, Inc., and H.B. Fuller Automotive Products, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Spectronics Corporation v. H.B. Fuller Company, Inc., and H.B. Fuller Automotive Products, Inc., 940 F.2d 631, 19 U.S.P.Q. 2d (BNA) 1545, 1991 U.S. App. LEXIS 16676, 1991 WL 138501 (Fed. Cir. 1991).

Opinion

CLEVENGER, Circuit Judge.

Spectronics Corporation (Spectronics) appeals the judgment of the United States District Court for the Eastern District of New York dismissing its action under the Declaratory Judgment Act, 28 U.S.C. § 2201 (1988), against H.B. Fuller Company, Inc., and H.B. Fuller Automotive Products, Inc., (collectively Fuller), for lack of an actual controversy. We affirm.

I

Spectronics manufactures and sells DY-GLO-12, a fluorescent leak detection additive used in automotive air conditioning systems. United States Patent No. 4,758,-366 (the ’366 patent), assigned to Fuller, claims certain fluorescent dyes used to detect leaks in air conditioning and refrigeration systems. Fuller sent letters to the industry in 1988 announcing the addition of the ’366 patent to its growing family of patents and its developing “patent strategy” with respect to its tracer dye line of products. The letters did not refer to Spec-tronics’ DYGLO-12 or any other competing products. Spectronics filed suit alleging that “an actual controversy exists” as to *633 whether it was infringing the ’366 patent claims, and that the purpose of Fuller’s letters to the industry “was to intimidate both [Spectronics] and [Spectronics’] customers in that anyone making, using or selling ‘DYGLO-12’ would be liable for such activities under [the ’366 patent].”

In its complaint, Spectronics asserted three causes of action: (1) entitlement to a declaratory judgment of invalidity or non-infringement of the claims of the ’366 patent under the Declaratory Judgment Act, 28 U.S.C. § 2201 (1988); (2) federal antitrust violations under the Sherman Act, 15 U.S.C. § 2 (1988); and (3) tortious interference with business relations. Before filing its answer, Fuller moved to dismiss all three counts under Fed.R.Civ.P. 12. Fuller’s motion was granted in part insofar as the parties stipulated to dismissal without prejudice of the antitrust and tortious interference counts, leaving at issue only the declaratory judgment count. Fuller then answered, filing a contingent counterclaim of patent infringement, and thereafter filed a second motion to dismiss the declaratory judgment action for lack of an actual controversy. During a hearing on that motion, Fuller presented the District Court with a declaration that the ’366 patent had been submitted to the Patent and Trademark Office (PTO) for reissue. The District Court denied the second motion.

Eight days later, Fuller filed in the District Court a covenant not to sue Spectron-ics for infringement of the ’366 patent claims. The covenant, styled a “Statement of Non Liability,” provides:

Defendant, H.B. Fuller Company, Inc., has filed a reissue application to reissue U.S. Patent No. 4,758,366 cancelling claims 1-18 and seeking new claims.
Spectronics has no liability to Defendants or any successors-in-interest to U.S. Patent No. 4,758,366 for infringement of claims 1-18 of U.S. Patent No. 4,758,366, and Defendants and any successors-in-interest to U.S. Patent No. 4,758,366 will not sue Spectronics for infringement of claims 1-18 of U.S. Patent No. 4,758,366.

Fuller filed a third motion to dismiss for lack of an actual controversy, which was granted in a memorandum opinion and order that incorporated “the [District] Court’s extensive discussions with counsel on the record at oral argument on August 17, 1990,” as permitted by Fed.R.Civ.P. 52(a). Spectronics Corp v. H.B. Fuller Co., CY 88-3803, slip op. at 1 (E.D.N.Y. Aug. 17, 1990) (incorporated oral argument and colloquy hereinafter cited as “Hearing Transcript”). In granting the third motion to dismiss, the District Court explained that:

[although this Court found on two previous occasions that a case or controversy existed in that plaintiff had shown the existence of facts underlying a “reasonable apprehension” that it would be sued for infringement of [the ’366 patent claims], defendants’ June 5, 1990 filing with the Patent and Trademark Office of a Reissue Application for this patent, taken in concert with its June 15, 1990, filing with this Court of a “Statement of Non-Liability,” operate to divest this Court of jurisdiction over this matter. Although plaintiff Spectronics Corporation may be charged with infringement of the claims that may result from the reissue application, plaintiff cannot, on the record before this Court, demonstrate an objectively reasonable apprehension that it will face an infringement suit on the ’366 patent.

The Declaratory Judgment Act provides, in pertinent part:

In a case of actual controversy within its jurisdiction, ... any court of the United States, upon the filing of an appropriate pleading, may declare the rights and other legal relations of any interested party seeking such declaration, whether or not further relief is or could be sought.

28 U.S.C. § 2201(a) (1988) (emphasis added).

The existence of an actual controversy is an absolute predicate for declara *634 tory judgment jurisdiction. Grain Processing Corp. v. American Maize-Products Co., 840 F.2d 902, 905, 5 USPQ2d 1788, 1791 (Fed.Cir.1988). When there is no actual controversy, the court has no discretion to decide the case. When there is an actual controversy and thus jurisdiction, the exercise of that jurisdiction is discretionary. Public Serv. Comm’n v. Wycoff Co., 344 U.S. 237, 241, 73 S.Ct. 236, 239, 97 L.Ed. 291 (1952); Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 735 n. 6, 6 USPQ2d 1685, 1688 n. 6 (Fed.Cir.1988). Dismissal in this case was not based on a discretionary decision not to exercise jurisdiction, but was compelled by the District Court’s conclusion that an actual controversy, and therefore jurisdiction, was altogether lacking.

Spectronics disputes none of the facts in the record, but argues the legal proposition that those facts established an actual controversy under the patent laws. In these circumstances, we review dismissal as a matter of law, keeping in mind that the District Court’s “view of the legal effect of the fact pattern before it is not to be lightly disregarded.” Arrowhead, 846 F.2d at 735, 6 USPQ2d at 1688.

The long established rule of law is that a declaratory judgment plaintiff must establish an actual controversy on the “totality of the circumstances.” Maryland Casualty Co. v. Pacific Coal & Oil Co.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

James Markey v. James Markey
Merit Systems Protection Board, 2023
Thaddeus A. Knight v. Department of Justice
Merit Systems Protection Board, 2015
Presby Patent Trust v Infiltrator Systems
2015 DNH 111 (D. New Hampshire, 2015)
Ford Motor Co. v. United States
992 F. Supp. 2d 1346 (Court of International Trade, 2014)
Microsoft Corporation v. Datatern, Inc.
755 F.3d 899 (Federal Circuit, 2014)
Cat Tech LLC v. TubeMaster, Inc.
528 F.3d 871 (Federal Circuit, 2008)
IVX ANIMAL HEALTH, INC. v. Burger
475 F. Supp. 2d 1264 (S.D. Florida, 2007)
Teva Pharmaceuticals USA, Inc. v. Food & Drug Administration
398 F. Supp. 2d 176 (District of Columbia, 2005)
Fort James Corporation v. Solo Cup Company
412 F.3d 1340 (Federal Circuit, 2005)
Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc.
395 F.3d 1324 (Federal Circuit, 2005)
In Re Columbia University Patent Litigation
343 F. Supp. 2d 35 (D. Massachusetts, 2004)
Gen-Probe Incorporated, Plaintiff-Cross v. Vysis, Inc.
359 F.3d 1376 (Federal Circuit, 2004)
Teva Pharmaceuticals USA, Inc. v. Abbott Laboratories
301 F. Supp. 2d 819 (N.D. Illinois, 2004)
Asahi Glass Co., Ltd. v. Pentech Pharmaceuticals
289 F. Supp. 2d 986 (N.D. Illinois, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
940 F.2d 631, 19 U.S.P.Q. 2d (BNA) 1545, 1991 U.S. App. LEXIS 16676, 1991 WL 138501, Counsel Stack Legal Research, https://law.counselstack.com/opinion/spectronics-corporation-v-hb-fuller-company-inc-and-hb-fuller-cafc-1991.